Associations between substance use, neuropsychological functioning and treatment response in psychosis

Psychiatry Research

Volumn 186, Issue 2-3, 2011, Pages 190-196

  DeVille, Madeleine ^a,b   Baker, Amanda ^a   Lewin, Terry J ^a,b,c   Bucci, Sandra ^d   Loughland, Carmel ^a,c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b Hunter New England Health Service   (Australia)

^c SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cognitive impairment; Neuropsychology; Psychoses; Substance use disorders

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ALCOHOLISM; ARTICLE; CANNABIS ADDICTION; COGNITIVE THERAPY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGY; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SUBSTANCE ABUSE; TREATMENT OUTCOME; TREATMENT RESPONSE; VOLUNTEER;

ADOLESCENT; ADULT; AGED; ASSOCIATION; CHI-SQUARE DISTRIBUTION; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 79952360523     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.08.025     Document Type: Article

References (41)

1. Addington J., Addington D. Neurocognitive and social functioning in schizophrenia. Schizophrenia Bulletin 1999, 25:173-182.
2. Addington J., Saeedi H., Addington D. The course of cognitive functioning in first episode psychosis: changes over time and impact on outcome. Schizophrenia Research 2005, 78:35-43.
3. Aharonovich E., Brooks A.C., Nunes E.V., Hasin D.S. Cognitive deficits in marijuana users: effects on motivational enhancement therapy plus cognitive behavioral therapy treatment outcome. Drug and Alcohol Dependence 2008, 95:279-283.
4. Akvardar Y., Tumuklu M., Akdede B.B., Ulas H., Kitis A., Alptekin K. Substance use among patients with schizophrenia in a university hospital. Bulletin of Clinical Psychopharmacology 2004, 14:191-197.
5. Allen D.N., Goldstein G., Aldarondo F. Neurocognitive dysfunction in patients diagnosed with schizophrenia and alcoholism. Neuropsychology 1999, 13:62-68.
6. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR 1994, American Psychiatric Association.
7. Baker A., Bucci S., Lewin T.J., Richmond R., Carr V.J. Comparisons between psychosis samples with different patterns of substance use recruited for clinical and epidemiological studies. Psychiatry Research 2005, 134:241-250.
8. Baker A., Bucci S., Lewin T.J., Kay-Lambkin F., Constable P.M., Carr V.J. Cognitive behavioural therapy for substance use disorders in people with psychotic disorders: randomised controlled trial. British Journal of Psychiatry 2006, 188:439-448.
9. Barrowclough C., Haddock G., Tarrier N., Lewis S.W., Moring J., O'Brien R., Schofield N., McGovern J. Randomized controlled trial of motivational interviewing, cognitive-behaviour therapy and family interventions for patients with comorbid schizophrenia and substance use disorders. American Journal of Psychiatry 2001, 158:1706-1713.
10. Bellack A.S., Bennett M.E., Gearon J.S., Brown C.H., Yang Y. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Archives of General Psychiatry 2006, 62:426-432.
11. Bennett M.E., Bellack A.S., Gearon J.S. Treating substance abuse in schizophrenia: an initial report. Journal of Substance Abuse Treatment 2001, 20:163-175.
12. Bowie C.R., Serper M.R., Riggio S., Harvey P.D. Neurocognition, symptomatology, and functional skills in older alcohol-abusing schizophrenia patients. Schizophrenia Bulletin 2005, 31:175-182.
13. Carr V.J., Lewin T.J., Neil A.L., Halpin S.A., Holmes S. Premorbid, psychosocial and clinical predictors of the costs of schizophrenia and other psychoses. British Journal of Psychiatry 2004, 184:517-525.
14. Darke S., Heather N., Hall W., Ward J., Wodak A. Estimating drug consumption in opioid users: reliability and validity of a 'recent use' episodes method. British Journal of Addiction 1991, 86:1311-1316.
15. First M.B., Gibbon M., Spitzer R.L., Williams J.B. Users guide for the Structured Clinical Interview for the DSM-IV AXIS-1 Disorder-Research Version-(SCID-1, Version 2.0 February 1996) 2003, Biometrics Research Department, New York State Psychiatric Institute, New York.
16. Fitzgerald D., Lucas S., Redoblado M.A., Winter V., Brennan J., Anderson J., Harris A. Cognitive functioning in young people with first episode psychosis: relationship to diagnosis and clinical characteristics. Australian and New Zealand Journal of Psychiatry 2004, 38:501-510.
17. Fletcher P.C., Honey G.D. Schizophrenia, ketamine and cannabis: evidence of overlapping memory deficits. Trends in Cognitive Sciences 2006, 10:167-174.
18. Gold J.M., Queern C., Iannone V.N., Buchanan R.W. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia, I: sensitivity, reliability, and validity. American Journal of Psychiatry 1999, 156:1944-1950.
19. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. American Journal of Psychiatry 1996, 153:321-330.
20. Green M.F., Nuechterlein K.H., Gold J.M., Barch D.M., Cohen J., Essock S., Fenton W.S., Frese F., Goldberg T.E., Heaton R.K., Keefe R.S.E., Kern R.S., Kraemer H., Stover E., Weinberger D.R., Zalcman S., Marder S.R. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry 2004, 56:301-307.
21. Hasin D.S., Trautman K.D., Miele G.M., Samet S., Smith M., Endicott J. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. American Journal of Psychiatry 1996, 153:1195-1201.
22. Hobart M.P., Goldberg R., Bartko J.J., Gold J.M. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia II: convergent/discriminant validity and diagnostic group comparisons. American Journal of Psychiatry 1999, 156:1951-1957.
23. Holzer L., Chinet L., Jaugey L., Plancherel B., Sofia C., Halfon O., Randolph C. Detection of cognitive impairment with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in adolescents with psychotic symptomatology. Schizophrenia Research 2007, 95:48-53.
24. Jablensky A., McGrath J., Herrman H., Castle D., Gureje O., Evans M., Carr V., Morgan V., Korten A., Harvey C. Psychotic disorders in urban areas: an overview of the study on low prevalence disorders. Australian and New Zealand Journal of Psychiatry 2000, 34:221-236.
25. Linszen D., van Amelsvoort T. Cannabis and psychosis: an update on course and biological plausible mechanisms. Current Opinion in Psychiatry 2007, 20:116-120.
26. Loughland C.M., Carr V.J., Lewin T.J., Barnard R.E. Potential sampling and recruitment source impacts in schizophrenia research. Psychiatry Research 2004, 125:117-127.
27. Loughland C.M., Lewin T.J., Carr V.J., Sheedy J., Harris A.W. RBANS neuropsychological profiles within schizophrenia sample recruited from non-clinical settings. Schizophrenia Research 2007, 89:232-242.
28. Mathias S., Lubman D.I., Hides L. Substance-induced psychosis: a diagnostic conundrum. Journal of Clinical Psychiatry 2008, 69:358-367.
29. McCleery A., Addington J., Addington D. Substance misuse and cognitive functioning in early psychosis: a 2year follow-up. Schizophrenia Research 2006, 88:187-191.
30. McEvoy J.P., Allen T.B. Substance use (including nicotine) in schizophrenic patients. Current Opinion in Psychiatry 2003, 16:199-205.
31. Michie P.T., Kent A., Stienstra R., Castine R., Johnston J., Dedman K., Wichmann H., Box J., Rock D., Rutherford E., Jablensky A. Phenotypic markers as risk factors in schizophrenia: neurocognitive functions. Australian and New Zealand Journal of Psychiatry 2000, 34:74-85.
32. Nuechterlein K.H., Green M.F., Kern R.S., Baade L.E., Barch D.M., Cohen J.D., Essock S., Fenton W.S., Frese F.J., Gold J.M., Goldberg T., Heaton R.K., Keefe R.S.E., Kraemer H., Mesholam-Gately R., Seidman L.J., Stover E., Weinberger D.R., Young A.S., Zalcman S., Marder S.R. The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. American Journal of Psychiatry 2008, 165:203-213.
33. Randolph C. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Test Manual 1998, Harcourt Brace and Company, San Antonio.
34. Riley E.M., McGovern D., Mockler D., Doku V.C.K., ÓCeallaigh S., Fannon D.G., Tennakoon L., Santamaria M., Soni W., Morris R.G., Sharma T. Neuropsychological functioning in first-episode psychosis - evidence of specific deficits. Schizophrenia Research 2000, 43:47-55.
35. Schofield P.W., Lee S.J., Lewin T.J., Lyall G., Moyle J., Attia J., McEvoy M. The Audio Recorded Cognitive Screen (ARCS): a flexible hybrid cognitive test instrument. Journal of Neurology, Neurosurgery and Psychiatry 2010, 81:602-607.
36. Sevy S., Robinson D.G., Holloway S., Alvir J.M., Woerner M.G., Bilder R., Goldman R., Lieberman J., Kane J. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatrica Scandinavica 2001, 104:367-374.
37. Stirling J., Lewis S., Hopkins R., White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophrenia Research 2005, 75:135-137.
38. Tucker P. Substance misuse and early psychosis. Australasian Psychiatry 2009, 17:291-294.
39. Wilk C.M., Gold J.M., Bartko J.J., Dickerson F., Fenton W.S., Knable M., Randolph C., Buchanan R.W. Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia. American Journal of Psychiatry 2002, 159:838-844.
40. Wilk C.M., Gold J.M., McMahon R.P., Humber K., Iannone V.N., Buchanan R.W. No, it is not possible to be schizophrenic yet neuropsychologically normal. Neuropsychology 2005, 19:778-786.
41. World Health Organization The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines 1992, World Health Organization, Geneva.